LEO Pharma reports outcomes from Phase IIb trial of atopic dermatitis therapy

LEO Pharma has reported positive topline outcomes from the randomised Phase IIb trial of the IL-22 receptor subunit alpha 1 (IL-22RA1) antagonist temtokibart, a potential new treatment for the adult population with moderate-to-severe atopic dermatitis (AD).